Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.59 |
| ▸ | FNTB | P49356 | 3/20 | 0.59 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897839 | 0.81 | FNTA (0.69) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL4902228 | 0.79 | FNTA (0.60) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL4897164 | 0.75 | FNTA (0.61) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL4893490 | 0.75 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL4894226 | 0.75 | FNTA (1.00) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL4888303 | 0.74 | FNTA (0.61) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL631711 | 0.70 | TAAR1 (1.00) | TAAR1 | |
| SCHEMBL4896739 | 0.70 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL14110649 | 0.68 | HDAC3 (0.50) | FNTAFNTBPGGT1BCYP1A2CYP2C19 | |
| SCHEMBL14189367 | 0.67 | TAAR1 (0.68) | FNTAFNTBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | FNTA 18/4885FNTB 38/4885PGGT1B 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.